Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 1;11(1):2096362. doi: 10.1080/2162402X.2022.2096362

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — OAd-MUC16-BiTE enhances antitumor efficacy in vivo. (a) Schematic experimental design. After treatment, tumor tissues were collected at the indicated time points. (b, e) Photographs of tumors after treatment, (b) the CDX model, (d) the PDX model. (c, f) Tumor volume and (d, g) mass were measured (Data represent the mean ± SD, n = 5). (c, d) the CDX model, (f, g) the PDX model. (h, i) IHC-stained tumor sections of the PDX model. Representative images of the virus HEXON (h) and 6× His tag (i). Scale bar: 50 μm.(j) HE staining of the major organs (heart, liver, spleen, lung, kidney and stomach) of C57/BL6 mice after different treatments. The scale bars are 100 μm. s.c. subcutaneous; i.v., intravenous; i.t., intratumoral; CDX, cell-derived xenograft; PDX, patient-derived xenograft; IHC, immunohistochemistry; HE, hematoxylin and eosin.